ARCHIVES

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

This article is from The Cancer Letter archive.

Vol. 26 No. 11 | November 28, 2003

Download PDF Visit The Full Archive

Related Articles

RFA On Promoters, Hormones, Other Cofactors Available

July 17, 1981

Guest Editorial: Gerard Silvestri calls for uniform guideline for CT screening for lung cancer

July 1, 2011

Efaproxyn Improved Survival Of Patients With Brain Mets

October 29, 2004

Taxol Patents Reveal Bristol Strategy to Safeguard Market Against Competitors

July 4, 1997

Clearinghouse Finds Five Compounds Pose Risk To Humans

March 2, 1979

Doctors Are Doing More Cancer Screening, ACS Survey Finds

March 30, 1990